All Comments by Paul Coleman
- Treatment of Alzheimer's disease. New developments.
- Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome.
- Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent.
- Neurofilament protein levels in CSF are increased in dementia.
- Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain.
- APLP2, a member of the Alzheimer precursor protein family, is required for correct genomic segregation in dividing mouse cells.
- Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome.
- The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients.
- Chronic (-) deprenyl administration increases dendritic arborization in CA3 neurons of hippocampus and AChE activity in specific regions of the primate brain.
- Neuropathologic diagnosis of Alzheimer disease: consensus between practicing neuropathologists?
- Regulation of expression, phosphorylation and biological activity of tau during differentiation in SY5Y cells.
- Quantification of cholinergic and select non-cholinergic mesopontine neuronal populations in the human brain.
- Occupational exposures to solvents and aluminium and estimated risk of Alzheimer's disease.
- An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease.
- Aloys Alzheimer, a coworker of Emil Kraepelin.